» Articles » PMID: 33884030

Downregulation of MiR-588 is Associated with Tumor Progression and Unfavorable Prognosis in Patients with Osteosarcoma

Overview
Journal Exp Ther Med
Specialty Pathology
Date 2021 Apr 22
PMID 33884030
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Osteosarcoma (OS) is a primary malignant tumor characterized by a high metastatic potential and poor prognosis. The dysregulation of miR-588 has been demonstrated to serve crucial roles in the progression of numerous types of cancer. The present study aimed to investigate the expression and function of miR-588 in the development of OS. To do so, clinical samples were collected and analyzed, and in vitro experiments were conducted. A total of 104 patients with OS were recruited between 2012 and 2014. The expression of miR-588 was analyzed by reverse transcription quantitative PCR. The association between miR-588 expression and the clinicopathological characteristics and survival rate of patients with OS was evaluated. Furthermore, Cell Counting Kit-8 and Transwell assays were used to evaluate the effect of miR-588 on the proliferation and the migratory and invasive abilities of various OS cell lines. The results demonstrated that miR-588 expression in OS tissues and cells was significantly lower compared with normal tissues and cells. In addition, miR-588 expression was closely associated with the Musculoskeletal Tumor Society (MSTS) staging of patients with OS. miR-588 expression and MSTS staging were therefore considered as independent indicators for the prognosis of patients with OS. In addition, miR-588 downregulation significantly stimulated the proliferation and migratory and invasive abilities of OS cells. Taken together, these findings indicated that miR-588 may serve as an independent prognostic factor and tumor suppressor in OS.

Citing Articles

CircORC2 promoted proliferation and inhibited the sensitivity of osteosarcoma cell lines to cisplatin by regulating the miR-485-3p/TRIM2 axis.

Chen T, Zhang Z, Tian C, Feng Y, He X, Jiang L J Cell Commun Signal. 2024; 18(2):e12029.

PMID: 38946721 PMC: 11208123. DOI: 10.1002/ccs3.12029.


CircECE1 promotes osteosarcoma progression through regulating RAB3D by sponging miR-588.

Liang Z, Shi Y, Guan Z J Orthop Surg Res. 2023; 18(1):587.

PMID: 37559140 PMC: 10410784. DOI: 10.1186/s13018-023-04045-4.


MiR-588 acts as an oncogene in ovarian cancer and increases the radioresistance of ovarian cancer cells.

Su X, Wang B, Zhang B, Pan S J Radiat Res. 2023; .

PMID: 37154623 PMC: 10214998. DOI: 10.1093/jrr/rrad033.


Analysis of microRNA expression in CD133 positive cancer stem‑like cells of human osteosarcoma cell line MG-63.

Shu X, Liu W, Liu H, Qi H, Wu C, Ran Y PeerJ. 2021; 9:e12115.

PMID: 34557357 PMC: 8420872. DOI: 10.7717/peerj.12115.

References
1.
Zhao N, Lin T, Zhao C, Zhao S, Zhou S, Li Y . MicroRNA-588 is upregulated in human prostate cancer with prognostic and functional implications. J Cell Biochem. 2017; . DOI: 10.1002/jcb.26417. View

2.
Picci P . Osteosarcoma (osteogenic sarcoma). Orphanet J Rare Dis. 2007; 2:6. PMC: 1794406. DOI: 10.1186/1750-1172-2-6. View

3.
Liu W, Zhang X, Liu P, Shen X, Lan T, Li W . Effects of berberine on matrix accumulation and NF-kappa B signal pathway in alloxan-induced diabetic mice with renal injury. Eur J Pharmacol. 2010; 638(1-3):150-5. DOI: 10.1016/j.ejphar.2010.04.033. View

4.
Meazza C, Scanagatta P . Metastatic osteosarcoma: a challenging multidisciplinary treatment. Expert Rev Anticancer Ther. 2016; 16(5):543-56. DOI: 10.1586/14737140.2016.1168697. View

5.
Qiao W, Cao N, Yang L . MicroRNA-154 inhibits the growth and metastasis of gastric cancer cells by directly targeting MTDH. Oncol Lett. 2017; 14(3):3268-3274. PMC: 5588056. DOI: 10.3892/ol.2017.6558. View